Lazard Capital Markets Healthcare Conference (Immunomedics) - Nov 23, 2011 - veltuzumab / Immunomedics; Anticipated updated results from P2 study of subcutaneous veltuzumab in immune thrombocytopenic purpura at ASH meeting in December 2011
Anticipated P2 trial update • Immunology • None
|